Table 1 First-line treatment in soft tissue sarcomas: prospective evidence
From: Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new
Study | Study phase | Drug and schedule | Patients | Overall response rate (%) | Progression-free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|
Cytotoxic agents | ||||||
Judson et al., 2014 [2] | III | Arm A: D (75 mg/m2) 3-weekly Arm B: D (25 mg/m2/day, days 1–3) + I (10 g/m2 over 4 days) 3-weekly | Arm A: 228 Arm B: 227 | Arm A: 14 Arm B: 26 | Arm A: 4.6 Arm B: 7.4 | Arm A: 12.8 Arm B: 14.3 |
Chawla et al., 2015 [6] | IIb | Arm A: D (75 mg/m2) 3-weekly Arm B: Aldoxorubicin (350 mg/m2) 3-weekly | Arm A: 40 Arm B: 83 | Arm A: 0 Arm B: 25 | Arm A: 2.7 Arm B: 5.6 | Arm A: 14.3 Arm B: 15.8 |
Gupta et al., 2016 [9] | II | Amrubicin 40 mg/m2/day, days 1–3, 3 weekly | 24 | 13 | 5.8 | 26 |
Ryan et al., 2016 [3] | III | Arm A: D (75 mg/m2) + P (150 mg/m2/day, days 1–3) 3-weekly Arm B: D (75 mg/m2) + placebo, 3-weekly | Arm A: 227 Arm B: 221 | Arm A: 28.3 Arm B: 19.9 | Arm A: 6 Arm B: 5.2 | Arm A: 15.9 Arm B: 16.9 |
Tap et al., 2016 [4] | III | Arm A: Evofosfamide (300 mg/m2) + D (75 mg/m2), 3-weekly Arm B: D (75 mg/m2) 3-weekly | Arm A: 317 Arm B: 323 | Arm A: 28.4 Arm B: 18.3 | Arm A: 6.3 Arm B: 6 | Arm A: 18.4 Arm B: 19 |
Seddon et al., 2015 [12] | III | Arm A: G (625 mg/m2 day 1 and 8) + Doc (75 mg/m2 day 8), 3-weekly Arm B: D (75 mg/m2), 3-weekly | Arm A: 128 Arm B: 129 | Arm A: 58.6 Arm B: 65.9 | Arm A: 5.6 Arm B: 5.3 | Arm A: 14.7 Arm B: 16.5 |
Bui-Nguyen et al., 2015 [13] | II b | Arm A: T (1.3 mg/m2) 3-hour infusion, 3-weekly Arm B: T (1.5 mg/m2) 24-hour infusion, 3-weekly Arm C: D (75 mg/m2) 3-weekly | Arm A: 47 Arm B: 43 Arm C: 43 | Arm A: 14.8 Arm B: 4.7 Arm C: 25.6 | Arm A: 2.8 Arm B: 3.1 Arm C: 5.5 | NA |
Martin-Broto et al., 2016 [14] | II | Arm A: T (1.1 mg/m2) 3-hours infusion + D (60 mg/m2), 3-weekly Arm B: D (75 mg/m2), 3-weekly | Arm A: 54 Arm B: 59 | Arm A: 17 Arm B: 17 | Arm A: 5.7 Arm B: 5.5 | Arm A: 13.3 Arm B: 13.7 |
Gelderblom et al., 2014 [15] | II | Arm A: Brostallicin (10 mg/m2), 3-weekly Arm B: D (75 mg/m2), 3-weekly | Arm A: 79 Arm B: 39 | Arm A: 3.9 Arm B: 22 | Arm A: 1.6 Arm B: 6 | NA |
Biological agents | ||||||
Tap et al., 2016 [11] | Ib/II | Arm A: Olaratumab (15 mg/kg) day 1 and 8 + D (75 mg/m2); 3-weekly Arm B: D (75 mg/m2), 3-weekly | Arm A: 66 Arm B: 67 | Arm A: 18.2 Arm B: 11.9 | Arm A: 6.6 Arm B: 4.1 | Arm A: 26.5 Arm B: 14.7 |